Journal article
Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile
A Latifi, K Abubaker, N Castrechini, AC Ward, C Liongue, F Dobill, J Kumar, EW Thompson, MA Quinn, JK Findlay, N Ahmed
Journal of Cellular Biochemistry | WILEY | Published : 2011
DOI: 10.1002/jcb.23199
Abstract
Epithelial mesenchymal transition (EMT) and cancer stem cells (CSC) have been associated with resistance to chemotherapy. Eighty percent of ovarian cancer patients initially respond to platinum-based combination therapy but most return with recurrence and ultimate demise. To better understand such chemoresistance we have assessed the potential role of EMT in tumor cells collected from advanced-stage ovarian cancer patients and the ovarian cancer cell line OVCA 433 in response to cisplatin in vitro. We demonstrate that cisplatin-induced transition from epithelial to mesenchymal morphology in residual cancer cells correlated with reduced E-cadherin, and increased N-cadherin and vimentin expres..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
The authors wish to thank Royal Women's Hospital Foundation, Women's Cancer Foundation, National Health and Medical Research Council of Australia (JKF, RegKey#441101) and Victorian Breast Cancer Research Consortium (EWT) for supporting this work. AL and KA are the recipients of Royal Women's Hospital Scholarship and Australian Postgraduate Award. The authors also wish to acknowledge the help of Ms. Julene Hallo in the acquisition of clinical samples.